Synthesis of novel GABA uptake inhibitors. 3. Diaryloxime and diarylvinyl ether derivatives of nipecotic acid and guvacine as anticonvulsant agents

Journal of Medicinal Chemistry

Volumn 42, Issue 18, 1999, Pages 3447-3462

  Knutsen, Lars J S ^a,f   Andersen, Knud Erik ^f   Lau, Jesper ^f   Lundt, Behrend F ^f   Henry, Rodger F ^b,f   Morton, Howard E ^b,f   Nærum, Lars ^f   Petersen, Hans ^c,f   Stephensen, Henrik ^f   Suzdak, Peter D ^d,f   Swedberg, Michael D B ^e,f   Thomsen, Christian ^f   Sørensen, Per O ^f  

^a Cerebrus Limited   (United Kingdom)

^b ABBOTT LABORATORIES   (United States)

^c H LUNDBECK A S   (Denmark)

^d GUILFORD PHARMACEUTICALS INC   (United States)

^e ASTRAZENECA R AND D   (Sweden)

^f NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4,4 DIPHENYL 3 BUTENYL)NIPECOTIC ACID; 4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; BENZODIAZEPINE RECEPTOR; TIAGABINE;

ARTICLE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; LIGAND BINDING;

ANIMALS; ANTICONVULSANTS; CARRIER PROTEINS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ETHERS; GABA ANTAGONISTS; GABA PLASMA MEMBRANE TRANSPORT PROTEINS; MEMBRANE PROTEINS; MEMBRANE TRANSPORT PROTEINS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NICOTINIC ACIDS; NIPECOTIC ACIDS; ORGANIC ANION TRANSPORTERS; OXIMES; PROLINE; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPTIC TRANSMISSION;

EID: 0033539049     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm981027k     Document Type: Article

References (82)

1. This work was initially presented in part as posters at the 33rd. National Organic Chemistry Symposium in Bozeman, Montana, June 1993, and at the Gordon Conference, Medicinal Chemistry, New London, New Hampshire, August 1997. For part 2, see: Andersen, K. E.; Begtrup, M.; Chorgade, M. S.; Lee, E. C.; Lau, J.; Lundt, B. F.; Petersen, H.; Sørensen, P. O.; Thøgersen, H. The Synthesis of Novel GABA uptake inhibitors. Part 2. Synthesis of 5-hydroxytiagabine, a Human Metabolite of the GABA Reuptake Inhibitor Tiagabine. Tetrahedron. 1994, 50, 8699-8710.
2. Costa, E. Building a Bridge Between Neurobiology and Mental Illness. J. Psychiat. Res. 1992, 26, 449-460.
3. DeLorenzo, R. Mechanisms of Action of Anticonvulsant Drugs. Epilepsia 1988, 29, S35-S47.
4. Natsch, S.; Hekster, Y. A.; Keyser, A.; Deckers, C. L. P.; Meinardi, H.; Renier, W. O. Newer anticonvulsant drugs: role of pharmacology, drug interactions and adverse reactions in drug choice. Drug Saf. 1997, 17, 228-240.
5. Walker, M. C.; Patsalos, P. N. Update on novel antiepileptic drugs. Emerging Drugs 1997, 2, 381-393.
6. Gram, L. Tiagabine: A Novel Drug with a GABAergic Mechanism of Action. Epilepsia 1994, 35, S85-S87.
7. Rogawski, M. A.; Porter, R. J. Antiepileptic Drugs: Pharmacological Mechanisms and Clinical Efficacy with Consideration of Promising Development Stage Compounds. Pharmacol. Rev. 1990, 42, 223-286.
8. Upton, N. Mechanisms of Action of New Antiepileptic Drugs: Rational Design and Serendipitous Findings. TIPS 1994, 15, 456-462
9. Chadwick, D. W. An overview of the efficacy and tolerability of new antiepileptic drugs. Epilepsia 1997, 38, S59-S62.
10. Andersen, K. E.; Braestrup, C.; Grønwald, F. C.; Jørgensen, A. S.; Nielsen, E. B.; Sonnewald, U.; Sørensen, P. O.; Suzdak, P. D.; Knutsen, L. J. S. The Synthesis of Novel GABA uptake inhibitors, 1. Elucidation of the Structure-Activity Studies leading to the choice of R1[4,4-bis(3-Methyl-2-thienyl)-3-piperidine carboxylic acid (Tiagabine) as an Anticonvulsant Drug Candidate. J. Med. Chem. 1993, 36, 1716-1725.
11. Mengel, H. Tiagabine. Epilepsia 1994, 29, S81-S84.
12. Taylor, C. P. GABA Receptors and GABAergic Synapses as Targets for Drug Development. Drug Dev. Res. 1990, 21, 151-160.
13. Bjorge, S.; Black, A.; Bockbrader, H.; Chang, T.; Gregor, V. E.; Lobbestael, S. J.; Nugiel, D.; Pavia, M. R.; Radulovic, L.; Woolf, T. Synthesis and Metabolic Profile of CI966: A Potent, Orally-Active Inhibitor of GABA Uptake. Drug Dev. Res. 1990, 21, 189193.
14. Pavia, M. R.; Lobbestael, S. J.; Nugiel, D.; Mayhugh, D. R.; Gregor, V. E.; Taylor, C. P.; Schwarz, R. D.; Brahce, L.; Vartanian, M. G. Structure-activity studies on benzhydrol-containing nipecotic acid and guvacine derivatives as potent, orally active inhibitors of GABA uptake. J. Med. Chem. 1992, 35, 4238-4248.
15. Taylor, C. P.; Vartanian, M. G.; Schwarz, R. D.; Rock, D. M.; Callahan, M. J.; Davis, M. D. Pharmacology of CI966: A Potent GABA Uptake Inhibitor, In Vitro and in Experimental Animals. Drug Dev. Res. 1990, 21, 195-215.
16. Sedman, A. J.; Gilmet, G. P.; Sayed, A. J.; Posvar, E. L. Initial Human Safety and Tolerance Study of a GABA Uptake Inhibitor, CI966: Potential Role of GABA as a Mediator in the Pathogenesis of Schizophrenia and Mania. Drug Dev. Res. 1990, 21, 235-242.
17. Suzdak, P. Lipophilic GABA Uptake Inhibitors: Biochemistry, Pharmacology and Therapeutic Potential. Drugs Fut. 1993, 18, 1129-1136.
18. Braestrup, C.; Nielsen, E. B.; Wolffbrandt, K. H.; Andersen, K. E.; Knutsen, L. J. S.; Sonnewald, U. Modulation of GABA Receptor Interaction with GABA Uptake Inhibitors. Int. Congr. Ser. Excerpta Med. 1987, 750 (Pharmacology), 125-128.
19. Nielsen, E. B.; Suzdak, P. D.; Andersen, K. E.; Knutsen, L. J. S.; Sonnewald, U.; Braestrup, C. Characterization of Tiagabine (NO-328), a New Potent and Selective GABA Uptake Inhibitor. Eur. J. Pharmacol. 1991, 196, 257266.
20. 3H-Tiagabine. Life Sci. 1992, 51, 1857-1868.
21. Smith, S. E.; Parvez, N. S.; Chapman, A. G.; Meldrum, B. S. The γ-Aminobutyric Acid Uptake Inhibitor, Tiagabine, is Anticonvulsant in Two Animal Models of Reflex Epilepsy. Eur. J. Pharmacol. 1995, 273, 259-265.
22. Halonen, T.; Nissinen, J.; Jansen, J. A.; Pitkanen, A. Tiagabine prevents seizures, neuronal damage and memory impairment in experimental status epilepticus. Eur. J. Pharmacol. 1996, 299, 69-81.
23. Dalby, N. O.; Nielsen, E. B. Tiagabine exerts an epileptogenic effect in amygdala kindling epileptogenesis in the rat. Neurosci. Lett. 1997, 229, 135-137. Morimoto, K.; Sato, H.; Yamamoto, Y.; Watanabe, T.; Suwaki, H. Antiepileptic effects of tiagabine, a selective GABA uptake inhibitor, in the rat kindling model of temporal lobe epilepsy. Epilepsia 1997, 38, 966-974.
24. Dalby, N. O.; Nielsen, E. B. Tiagabine exerts an epileptogenic effect in amygdala kindling epileptogenesis in the rat. Neurosci. Lett. 1997, 229, 135-137. Morimoto, K.; Sato, H.; Yamamoto, Y.; Watanabe, T.; Suwaki, H. Antiepileptic effects of tiagabine, a selective GABA uptake inhibitor, in the rat kindling model of temporal lobe epilepsy. Epilepsia 1997, 38, 966-974.
25. Suzdak, P. D.; Jansen, J. A. A review of the preclinical pharmacology of tiagabine - a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995, 36, 612-626.
26. Schousboe, A.; Larsson, O. M.; Krogsgaard-Larsen, P. GABA Uptake Inhibitors as Anticonvulsants. In GABA Mechanisms in Epilepsy; Tunnicliff, G., Raess, B. U., Eds.; Wiley-Liss: New York, 1991; p 165-187. Update on the mechanism of action of antiepileptic drugs.
27. Bauer, J.; Stawowy, B.; Lenders, T.; Bettig, U.; Elger, C. E. Efficacy and tolerability of tiagabine - results of an add-on study in patients with refractory partial seizures. J. Epilepsy 1995, 8, 83-86.
28. Meldrum, B. S. Update on the mechanism of action of anti-epileptic drugs. Epilepsia 1996, 37, S4-S11.
29. Benmenachem, E. International experience with tiagabine add-on therapy. Epilepsia 1995, 36, S14-S21.
30. Tiagabine, Gabitril, Tiabex. Drugs Fut. 1997, 22, 1396-1397.
31. Sachdeo, R. C.; Biton, V.; Boellner, S. W.; Schachter, S. C.; Alto, G. H.; Kaply, C. W.; Phillips, H. B.; Kardatzke, D.; Pixton, G.; Sommerville, K. W. Long-term safety of tiagabine-HC1. Epilepsia 1995, 36, 283-283.
32. Uthman, B.; Rowan, A. J.; Ahmann, P.; Wannamaker, B.; Schachter, S.; Rask, C. Safety and efficacy of 3 dose levels of tiagabine-HC1 versus placebo as adjunctive treatment for complex partial seizures. Ann. Neurol. 1993, 34, 272.
33. Dodrill, C. B.; Arnett, J. L.; Sommerville, K. W.; Shu, V. Cognitive and quality-of-life effects of differing dosages of tiagabine in epilepsy. Neurology 1997, 48, 1025-1031.
34. Mengel, H. B.; Pierce, M. W.; Mant, T.; Christensen, M. S.; Gustafson, L. Tiagabine Safety and Tolerance During 2-weeks Multiple Dosing to Healthy Volunteers. Epilepsia 1991, 32 (Suppl. 1).
35. Chadwick, D.; Richens, A.; Duncan, A.; Dam, M.; Gram, L.; Morrow, J.; Mengel, H.; Shu, V.; Mc. Kelvy, J. F.; Pierce, M. W. Tiagabine Hydrochloride. Safety and Efficacy as Adjunctive Treatment for Complex Partial Seizures. Epilepsia 1991, 32 (Suppl. 3).
36. Ali, F. E.; Bondinell, W. E.; Danbridge, P. A.; Frazee, J. S.; Garvey, E.; Girard, G. R.; Kaiser, C.; Ku, T. W.; Lafferty, J. J.; Moonsammy, G. I.; Oh, H. J.; Rush, J. A.; Setler, P. E.; Stringer, O. D.; Venslavsky, J. W.; Volpe, B. W.; Yunger, L. M.; Zirkle, C. L. Orally Active and Potent Inhibitors of Gamma Aminobutyric Acid uptake. J. Med. Chem. 1985, 28, 653-660.
37. Yunger, L. M.; Fowler P. J.; Zarevics, P.; Setler, P. E. Novel Inhibitors of γ-Aminobutyric Acid (GABA) Uptake: Anticonvulsant Actions in Rats and Mice. J. Pharm. Exp. Ther. 1984, 228, 109-115.
38. Krogsgaard-Larsen, P.; Hjeds, H.; Falch, E.; Joergensen, F. S.; Nielsen, L. Recent Advances in GABA Agonists, Antagonists and Uptake Inhibitors: Structure-Activity Relationships and Therapeutic Potential. Adv. Drug. Res. 1988, 17, 381-456.
39. Krogsgaard-Larsen, P.; Falch, E.; Larason, O. M.; Schousboe, A. GABA Uptake Inhibitors; Relevance to Antiepileptic Drug Research. Epilepsy Res. 1987, 1, 7793.
40. 3H]-GABA into Rat Brain Synaptosomes. Acta Pharmacol. Toxicol. 1978, 42, 7376.
41. Falch, E.; Krogsgaard-Larsen, P. GABA Uptake Inhibitors. Syntheses and Structureactivity Studies on GABA Analogues Containing Diarybutenyl and Diarylmethoxyalkyl N-substituents. Eur. J. Med. Chem. 1991, 26, 6978.
42. N'Goka, V.; Schlewer, G.; Linget, J.-M.; Chambon, J.-P.; Wermuth, C.-G. GABA-Uptake Inhibitors: Construction of a General Pharmacophore Model and Successful Prediction of a New Representative. J. Med. Chem. 1991, 34, 2547-2557.
43. Falch, E.; Larsson, O. M.; Schousboe, A.; Krogsgaard-Larsen, P. GABA-A agonists and GABA Uptake Inhibitors: Structure-Activity Relationships. Drug Dev. Res. 1990, 21, 169-188.
44. Dhar, T. G. M.; Borden, L. A.; Tyagarajan, S.; Smith, K. E.; Branchek, T. A.; Weinshank, R. L.; Gluchowski, C. Design, Synthesis and Evaluation of Substituted Triarylnipecotic Acid Derivatives as GABA Uptake Inhibitors: Identification of a Ligand with Moderate Affinity and Selectivity for the Cloned Human GABA Transporter GAT-3. J. Med. Chem. 1994, 37, 2334. See also refs 48-51 and Dhar, T. G. M.; Nakanishi, H.; Borden, L. A.; Gluchowski, C. On the bioactive conformation of the GABA uptake inhibitor SK&F 89976A. BioMed. Chem. Lett. 1996, 1535-1540.
45. Dhar, T. G. M.; Borden, L. A.; Tyagarajan, S.; Smith, K. E.; Branchek, T. A.; Weinshank, R. L.; Gluchowski, C. Design, Synthesis and Evaluation of Substituted Triarylnipecotic Acid Derivatives as GABA Uptake Inhibitors: Identification of a Ligand with Moderate Affinity and Selectivity for the Cloned Human GABA Transporter GAT-3. J. Med. Chem. 1994, 37, 2334. See also refs 48-51 and Dhar, T. G. M.; Nakanishi, H.; Borden, L. A.; Gluchowski, C. On the bioactive conformation of the GABA uptake inhibitor SK&F 89976A. BioMed. Chem. Lett. 1996, 1535-1540.
46. Knutsen, L. J. S.; Andersen, K. E.; Jørgensen, A. S.; Sonnewald, U. Azacyclic Carboxylic Acid Derivatives, Their Preparation and Use. Novo Nordisk A/S, U.S. Patent 5,039,685, August 13, 1991.
47. Knutsen, L. J. S.; Jørgensen, A. S.; Andersen, K. E.; Sonnewald, U. N-Substituted Azaheterocyclic Carboxylic Acids and Pharmaceutical Uses. Novo Nordisk A/S, U.S. Patent 5,071,859, December 10, 1991.
48. 2 receptor ligands in different chemoconvulsive models. Eur. J. Pharmacol. 1993, 224, 221-228.
49. Suzdak, P. D.; Frederiksen, K.; Andersen, K. E.; Sørensen, P. O.; Knutsen, L. J. S.; Nielsen, E. B. NNC-711, a Novel Potent and Selective GABA Uptake Inhibitor: Pharmacological Characterization. Eur. J. Pharmacol. 1992, 223, 189-198. For DMCM method descriptions, see also ref 19 and Swedberg, M. D. B.; Jacobsen, P.; Honoré, T. Anticonvulsant, anxiolytic and discriminative effects of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline (NBQX). J. Pharmacol. Exp. Ther. 1995, 274, 1113-1121.
50. Suzdak, P. D.; Frederiksen, K.; Andersen, K. E.; Sørensen, P. O.; Knutsen, L. J. S.; Nielsen, E. B. NNC-711, a Novel Potent and Selective GABA Uptake Inhibitor: Pharmacological Characterization. Eur. J. Pharmacol. 1992, 223, 189-198. For DMCM method descriptions, see also ref 19 and Swedberg, M. D. B.; Jacobsen, P.; Honoré, T. Anticonvulsant, anxiolytic and discriminative effects of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline (NBQX). J. Pharmacol. Exp. Ther. 1995, 274, 1113-1121.
51. Borden, L. A. GABA transporter heterogeneity: pharmacology and cellular localization. Neurochem. Int. 1996, 29, 335-356. Note that this article and ref 43 utilize different terminology for the GAT transporters from that in ref 49.
52. Liu, Q. R.; Lopez-Corcurera, B.; Mandiyan, S.; Nelson, H.; Nelson, N. Molecular Characterization of Four Pharmacologically Distinct γ-Aminobutyric Acid Transporters in Mouse Brain. J. Biol. Chem. 1993, 268, 2106-2112.
53. Borden, L. A.; Dhar, T. G. M.; Smith, K. E.; Weinshank, R. L.; Branchek, T. A.; Gluchowski, C. Tiagabine, SK&F 89976A, CI966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur. J. Pharmacol. 1994, 269, 219-224.
54. -) -coupled gamma-aminobutyric acid transporter from rat brain. J. Biol Chem. 1997, 272, 1203-1210.
55. Program Spartan Version 4.0, available from Wave Function, Inc., 18401 Von Karman, Suite 370, Irvine, CA 92715. Ab initio level used for the calculations was HF 6-31G**.
56. 47 is marketed as a pharmacological tool by Research Biochemicals, Inc., One Strathmore Road, Natick, MA 017602418.
57. Richards, D. A.; Bowery, N. G. Comparative effects of the GABA uptake inhibitors, tiagabine and NNC-711, on extracellular GABA levels in the rat ventrolateral thalamus. Neurochem. Res. 1996, 21, 135-140.
58. Akkerman, A. M.; De Jongh, D. K.; Veldstra, H. Synthetic Oxytocics. I. 3-(Piperidyl-(N)-Methyl)indoles and Related Compounds. Rec. Trav. Chim. 1951, 70, 899-916. Bettoni, G.; Duranti, E.; Tortorella, V. Absolute Configuration and Optical Purity of 3-Substituted Piperidines. Gazz. Chim. Ital. 1972, 102, 189195.
59. Akkerman, A. M.; De Jongh, D. K.; Veldstra, H. Synthetic Oxytocics. I. 3-(Piperidyl-(N)-Methyl)indoles and Related Compounds. Rec. Trav. Chim. 1951, 70, 899-916. Bettoni, G.; Duranti, E.; Tortorella, V. Absolute Configuration and Optical Purity of 3-Substituted Piperidines. Gazz. Chim. Ital. 1972, 102, 189195.
60. Kellogg, R. M.; Schaap, A. P.; Harper, E. T.; Wynberg, H. Acid-Catalysed Brominations, Deuterations, Rearrangements of Thiophenes under Mild Conditions. J. Org. Chem. 1968, 33, 2902-2909.
61. Buehler, E. Alkylation of syn-and anti-Benzaldoximes. J. Org. Chem. 1967, 32, 261-264.
62. See, for example: Laforest, J.; Thuiller, G. Etude de la configuration d'oximes a activite cardiotrope. J. Heterocycl. Chem. 1977, 14, 793-796; Haney, W. G.; Brown, R. G.; Isaacson, E. I.; Delgado, J. N. Synthesis and Structure Activity Relationships of Selected Isomeric Oxime O-Ethers as anticholinergic agents. J. Pharm. Sci. 1977, 66, 1602-1606. Conde, S.; Corral, C.; Lissavetzky, J. E-and Z-isomerism of 2-acetylthiophene oximes. J. Heterocycl. Chem. 1985, 22, 301-304.
63. See, for example: Laforest, J.; Thuiller, G. Etude de la configuration d'oximes a activite cardiotrope. J. Heterocycl. Chem. 1977, 14, 793-796; Haney, W. G.; Brown, R. G.; Isaacson, E. I.; Delgado, J. N. Synthesis and Structure Activity Relationships of Selected Isomeric Oxime O-Ethers as anticholinergic agents. J. Pharm. Sci. 1977, 66, 1602-1606. Conde, S.; Corral, C.; Lissavetzky, J. E-and Z-isomerism of 2-acetylthiophene oximes. J. Heterocycl. Chem. 1985, 22, 301-304.
64. See, for example: Laforest, J.; Thuiller, G. Etude de la configuration d'oximes a activite cardiotrope. J. Heterocycl. Chem. 1977, 14, 793-796; Haney, W. G.; Brown, R. G.; Isaacson, E. I.; Delgado, J. N. Synthesis and Structure Activity Relationships of Selected Isomeric Oxime O-Ethers as anticholinergic agents. J. Pharm. Sci. 1977, 66, 1602-1606. Conde, S.; Corral, C.; Lissavetzky, J. E-and Z-isomerism of 2-acetylthiophene oximes. J. Heterocycl. Chem. 1985, 22, 301-304.
65. (a) Ashwood, M. S.; Bell, L. A.; Houghton, P. G.; Wright, S. H. B. Synthesis of 1,1-Diaryl-2,-2-dimethoxyethanes. Synthesis 1988, 379-381.
66. (b) Borch, R. F. A New Procedure for the Darzen's Synthesis of Glycidic Esters. Tetrahedron Lett. 1972, 36, 3761-3763.
67. Martin, S. F. Synthesis of Aldehydes, Ketones and Carboxylic Acids from Lower Carbonyl Compounds by C-C Coupling Reactions. Synthesis 1979, 633-665.
68. Maruoka, K.; Nagahara S.; Ooi, T.; Yamamoto, H. An Efficient, Catalytic Procedure for Epoxide Rearrangement. Tetrahedron Lett. 1989, 30, 5607-5610.
69. (e) Meyers, A. I.; Jagdmann, G. E. Enamidines. Versatile Vehicles for Homologation of Carbonyl Compounds. J. Am. Chem. Soc. 1982, 104, 877-879.
70. (f) Mateson, D. S.; Moody, R. J. Homologation of Carbonyl Compounds to Aldehydes with Lithium Bis(ethylenedioxyboryl)methide. J. Org. Chem. 1980, 45, 1091-1095.
71. Blicke, F. F.; Faust, J. A. Antispasmodics. XV. β-Diethylaminoethyl Esters of β,β-Diphenylglycidic, β,β-Diphenyllactic and β,β-Diphenylglyceric Acids. J. Am. Chem. Soc. 1954, 76, 3156-3159.
72. Ridogrel (R-68070). Drugs Fut. 1991, 16, 488-489.
73. vant Reit, B.; Elford, H. L. Amidox. Drugs Fut. 1991, 16, 990-991.
74. De Chaffoy de Courcelles, D.; De Loore, K.; Freyne, E.; Janssen, P. A. J. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds. J. Pharmacol. Exp. Ther. 1992, 263, 6-14.
75. Schwarz, R. D.; Davis, R. E.; Jaen, J. C.; Spencer, C. J.; Tecle, H.; Thomas, A. J. Characterization of muscarinic agonists in recombinant cell lines. Life Sci. 1993, 52, 465-72.
76. Nielsen, L.; Brehm, L.; Krogsgaard-Larsen, P. GABA agonists and uptake inhibitors. Synthesis, absolute stereochemistry, and enantioselectivity of (R)-(-)-and (S)-(+)-homo-β-proline J. Med. Chem. 1990, 33, 71-7.
77. Dalby, N. O.; Thomsen, C.; Fink Jensen, A.; Lundbeck, J.; Sokilde, B.; Man, C. M.; Sorensen, P. O.; Meldrum, B. Anticonvulsant properties of two GABA uptake inhibitors NNC 05-2045 and NNC 05-2090, not acting preferentially on GAT-1. Epilepsy Res. 1997, 28, 51-61.
78. Thomsen, C.; Sorensen, P. O.; Egebjerg, J. 1-(3-(9H-Carbazol-9-yl)-1-propy1)-4-(2-methoxyphenyl)-4-piperidinol, a novel subtype-selective inhibitor of the mouse type-II GABA transporter. Br. J. Pharmacol. 1997, 120, 983-985.
79. Still, W. C.; Kahn, M.; Mitra, A. Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution. J. Org. Chem. 1978, 43, 29235.
80. Morlacchi, F.; Cardellini, M.; Liberatore, F. Preparation of unsaturated heterocyclic compounds, II. Synthesis of guvacine. Ann. Chim. 1967, 57, 1456-1461.
81. Hassner, A.; Alexanian, V. Direct room temperature esterification of carboxylic acids. Tetrahedron Lett. 1978, 46, 4475-4478.
82. Braestrup, C.; Nielsen, E. B.; Sonnewald, U.; Knutsen, L. J. S.; Andersen, K. E.; Jansen, J. A.; Frederiksen, K.; Andersen, P. H.; Mortensen, A.; Suzdak, P. D. (R)-N-(4,4-Bis-(3-Methyl-2-Thienyl)-but-3-en-1-yl)nipecotic acid binds with high affinity to the brain γ-aminobutyric acid uptake carrier. J. Neurochem. 1990, 54, 639-647.